Rakuten Investment Management Inc. Makes New $10.57 Million Investment in Boston Scientific Corporation $BSX

Rakuten Investment Management Inc. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, Holdings Channel reports. The fund bought 243,100 shares of the medical equipment provider’s stock, valued at approximately $10,570,000.

Several other institutional investors and hedge funds have also modified their holdings of BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Sfam LLC acquired a new stake in Boston Scientific during the fourth quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. bought a new position in Boston Scientific during the 4th quarter worth $33,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.3%

Shares of BSX opened at $46.82 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market capitalization of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. The stock has a fifty day moving average of $46.56 and a 200-day moving average of $56.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BSX shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Needham & Company LLC decreased their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Finally, Barclays reduced their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.